Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to advance cognitive digital therapy, focusing on the assessment and training of cognitive functions from January 1, 2026, to December 30, 2026 [1] Group 1 - The collaboration aims to deepen technological exploration and productization in the mental health field, integrating cutting-edge AI algorithms with clinical needs to create more precise and universal digital therapy products [1] - The partnership will contribute to the establishment of industry standards and market normalization, enhancing the company's solution credibility and facilitating nationwide product promotion [2] - The project focuses on enhancing service capabilities in mental health welfare institutions and community settings, significantly expanding the coverage of the company's products and services while creating social benefits and new market growth opportunities [2] Group 2 - The collaboration with Beijing Jianguo Medical strengthens the company's network with national research institutions, accumulating real-world data that will drive algorithm iteration, product optimization, and innovative research and development [2]

Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to develop and promote cognitive digital therapy, aiming for standardization and accessibility in the field of cognitive disorders [1][2]. Group 1: Deepening Technical Exploration - The collaboration will enhance technical exploration and productization in mental health by integrating cutting-edge AI algorithms with clinical needs, leading to more precise and universal technology products [1]. Group 2: Establishing Industry Standards - The project will contribute to the establishment of national standards and market normalization, accumulating high-level evidence-based medical data and enhancing the authority of the company's solutions for nationwide promotion [2]. Group 3: Expanding Service Network - The initiative focuses on mental health welfare institutions and community settings, aiming to improve service capabilities for cognitive disorders, thereby increasing market penetration and creating significant social benefits [2]. Group 4: Strengthening Research Collaboration - The partnership with Beijing Jianguo Medical will solidify the company's collaboration network with national research institutions, with real-world data from long-term research cohorts serving as valuable assets for algorithm iteration and product optimization [2].

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance Metrics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [2][3]. - The highest price reached was 13.78 HKD, while the lowest was 5.22 HKD, with a total volume of 3.812 billion shares traded during this period [3]. Group 2: Market Dynamics - The significant turnover rate of 30.107% indicates a major shift in the shareholder structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [3]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support level for future price movements [3]. Group 3: Trading Behavior Analysis - The K-line patterns revealed a complex interplay between bulls and bears, with four days of price increases but only three days showing positive closing prices, indicating a fierce battle between buying and selling pressures [4][6]. - Despite the apparent selling pressure, the volume of buying (3.572 billion shares) was significantly higher than selling (0.24 billion shares), demonstrating strong underlying demand [7]. Group 4: Investor Composition - Data shows that southbound funds were the primary drivers of this rally, with nearly 944.3 million shares acquired through the Hong Kong Stock Connect within just five days, representing 0.7458% of the total issued shares [8][10]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [10]. Group 5: Future Outlook - As of September 15, the stock was trading at 10.22 HKD, reflecting a 36.27% increase for the day, with a trading volume of 21.43 billion HKD, suggesting a transition into a new phase of market activity [11]. - The market is currently in a high-level consolidation phase after a rapid price increase, with future price stability dependent on continued inflows from southbound funds and the company's ability to validate its growth potential [11].

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance and Market Dynamics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [1][2]. - The turnover rate of 30.107% indicates a significant shift in shareholding structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [2]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support line for future price movements [2]. Group 2: Market Sentiment and Trading Behavior - The K-line pattern during this period showed a paradox where the stock rose for four days but only recorded three bullish candles, indicating a fierce battle between bulls and bears [3][5]. - Despite the apparent selling pressure, the volume of buying was significantly higher, with bullish volume at 3.572 billion shares, which is 14.88 times the bearish volume, indicating strong buying interest [6]. Group 3: Investor Composition and Market Drivers - Southbound funds were identified as the primary drivers of this rally, with nearly 944.3 million shares acquired through the Stock Connect channels within just five days, representing 0.7458% of the total issued shares [7][9]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [9]. Group 4: Future Outlook - The stock is currently in a high volatility phase following a significant price increase, with ongoing battles between buyers and sellers in the 10.00-11.00 HKD range [10]. - The future price stability will depend on two key factors: the continued inflow of southbound funds and the company's ability to validate its high growth potential to match the new valuation [10].